Harrow Launches Program to Enhance Access and Affordability of Ophthalmic Medications

Harrow Launches Access and Affordability Program for Ophthalmic Products

Harrow, a leading North American eyecare pharmaceutical company, introduces an Access and Affordability Program designed to improve patient access to its ophthalmic medications. This initiative focuses on reducing the prices of popular products, including VIGAMOX® and MAXIDEX®, which took effect this week. The program aligns with Harrow's commitment to eliminating financial barriers that often prevent patients from obtaining essential eyecare treatments. By implementing this strategy, the company aims to enhance patient outcomes and overall quality of life for those in need of sight-preserving medications.

The Access and Affordability Program represents a proactive step toward addressing the challenges patients face regarding medication costs. High insurance co-payments frequently make necessary treatments unaffordable, leading to inadequate access to vital eyecare. To further this initiative, Harrow has partnered with GoodRx, the premier prescription savings platform in the United States. This collaboration enables patients to secure discounts on select products such as FLAREX®, ILEVRO®, and VIGAMOX®, providing a cash-pay option for those without sufficient insurance coverage. Patients can conveniently access these discounts through the GoodRx website or mobile application, streamlining the process of obtaining their prescriptions.

Mark L. Baum, Harrow's Chairman and CEO, underscores the company's founding mission to assist patients in managing and preserving their sight. He articulates that both the pricing strategy and the partnership with GoodRx signify considerable progress toward this goal. The changes not only benefit patients by making vital medications more accessible but also create a favorable environment for shareholders. Harrow's ongoing dedication to making its innovative ophthalmic products available and affordable reflects its commitment to supporting eyecare professionals in their crucial role of preserving sight for millions of patients annually.

In addition to the Access and Affordability Program, Harrow recently reported strong financial results for the third quarter of 2024. The company achieved a 44% year-over-year revenue growth, totaling $49.26 million, despite a net loss of $4.22 million for the quarter. The gross margin increased to 76%, demonstrating the company's robust financial health and operational efficiency.

Harrow continues to focus on the discovery, development, and commercialization of innovative ophthalmic products, ensuring that its mission to support patient care remains steadfast. The Access and Affordability Program and the partnership with GoodRx are integral components of Harrow's strategy to enhance patient access and improve overall health outcomes in the eyecare industry.